Drug Trial Radar · NCT03422536
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Dec 5, 2017
Primary completion
Mar 29, 2022
Study completion Apr 5, 2022
Sponsor
- Lead sponsor
- University of ArizonaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.
Conditions
- Head and Neck Basaloid Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Unknown Primary Origin
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IV Oropharyngeal Squamous Cell Carcinoma
- Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
- Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVB Oropharyngeal Squamous Cell Carcinoma
- Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Head and Neck Cancer
- Oropharyngeal Cancer
- HNSCC
- Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Interventions
CetuximabBiological
Given IV
FiclatuzumabDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From the date of randomization until the date of progression or death, assessed up to 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
Yale Cancer Center
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.